KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current LiabilitiesPayablesPrepaid AssetsRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Palvella Therapeutics (PVLA) Other Non-Current Liabilities (2016 - 2026)

Palvella Therapeutics has reported Other Non-Current Liabilities over the past 8 years, most recently at $6000.0 for Q4 2020.

  • Quarterly Other Non-Current Liabilities changed N/A to $6000.0 in Q4 2020 from the year-ago period, while the trailing twelve-month figure was $6000.0 through Dec 2020, changed N/A year-over-year, with the annual reading at $6000.0 for FY2020, N/A changed from the prior year.
  • Other Non-Current Liabilities was $6000.0 for Q4 2020 at Palvella Therapeutics, down from $12.1 million in the prior quarter.
  • Over five years, Other Non-Current Liabilities peaked at $12.3 million in Q2 2019 and troughed at $6000.0 in Q4 2020.
  • The 5-year median for Other Non-Current Liabilities is $40902.5 (2016), against an average of $1.6 million.
  • Year-over-year, Other Non-Current Liabilities crashed 86.59% in 2016 and then skyrocketed 37656.25% in 2019.
  • A 5-year view of Other Non-Current Liabilities shows it stood at $47000.0 in 2016, then decreased by 21.28% to $37000.0 in 2017, then fell by 27.03% to $27000.0 in 2018, then soared by 44648.15% to $12.1 million in 2019, then plummeted by 99.95% to $6000.0 in 2020.
  • Per Business Quant, the three most recent readings for PVLA's Other Non-Current Liabilities are $6000.0 (Q4 2020), $12.1 million (Q3 2019), and $12.3 million (Q2 2019).